Also found in: Medical.
ANTI-HBeAntibody to Hepatitis B e Antigen (blood testing)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Screening for antibody against anti-HBc total, anti-HBc IgM, anti-HBs, and anti-HBe was done by chemiluminescence immunoassays (CLIA).
2) Previous HBV infection group (negative HBsAg and HBV-DNA, positive anti-HBe and/or anti- HBc): This group was administered with 10 mg/d LEF for at least 6 months.
After HBeAg seroconversion, some patients reach the fourth phase as HBeAg-negative chronic hepatitis B characterized by negative HBeAg, positive anti-HBe, detectable HBV-DNA ([10.sup.4]-[10.sup.8] copies/mL), and elevated aminotransferases.
loss of HBeAg and appearance of anti-HBe (antibody to HBeAg).
Anti-HBe was detected in 34 (66.7%) patients with genotype D, in 6 (24.0%) patients with genotype A, in 13 (72.2%) cases with genotype C.
Therapy should continue for at least 6 months after elimination of HBeAg and emergence of anti-HBe. Patients should be monitored for relapse after cessation of therapy.